Metformin / Placebo treatment for 4 months — Competitive Intelligence Brief

Metformin / Placebo treatment for 4 months (Metformin / Placebo treatment for 4 months) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule

Target snapshot

Metformin / Placebo treatment for 4 months (Metformin / Placebo treatment for 4 months) — Norwegian University of Science and Technology. Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin / Placebo treatment for 4 months TARGET	Metformin / Placebo treatment for 4 months	Norwegian University of Science and Technology	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin and roflumilast	metformin and roflumilast	University Medical Centre Ljubljana	marketed	Combination therapy: biguanide and phosphodiesterase-4 inhibitor	Metformin: mitochondrial glycerophosphate dehydrogenase; Roflumilast: phosphodiesterase-4 (PDE-4)
metformin 0.85 twice daily for 6 months	metformin 0.85 twice daily for 6 months	Xiang Guang-da	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
hypoglycemic Agents(metformin)	hypoglycemic Agents(metformin)	First Affiliated Hospital of Wenzhou Medical University	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Placebo-Metformin	Placebo-Metformin	Steno Diabetes Center Copenhagen	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Metformin Large Pack	Metformin Large Pack	GlaxoSmithKline	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial complex I
rosiglitazone-metformin	rosiglitazone-metformin	GlaxoSmithKline	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class